MIST vs. XNCR, SIGA, OPT, ARVN, OLMA, KOD, ATYR, AQST, ESPR, and IVA
Should you be buying Milestone Pharmaceuticals stock or one of its competitors? The main competitors of Milestone Pharmaceuticals include Xencor (XNCR), Siga Technologies (SIGA), Opthea (OPT), Arvinas (ARVN), Olema Pharmaceuticals (OLMA), Kodiak Sciences (KOD), aTyr Pharma (ATYR), Aquestive Therapeutics (AQST), Esperion Therapeutics (ESPR), and Inventiva (IVA). These companies are all part of the "pharmaceutical products" industry.
Milestone Pharmaceuticals vs. Its Competitors
Milestone Pharmaceuticals (NASDAQ:MIST) and Xencor (NASDAQ:XNCR) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their analyst recommendations, institutional ownership, risk, media sentiment, profitability, valuation, dividends and earnings.
Milestone Pharmaceuticals presently has a consensus target price of $4.50, indicating a potential upside of 135.60%. Xencor has a consensus target price of $22.25, indicating a potential upside of 161.76%. Given Xencor's stronger consensus rating and higher probable upside, analysts plainly believe Xencor is more favorable than Milestone Pharmaceuticals.
Milestone Pharmaceuticals has a beta of 0.6, suggesting that its stock price is 40% less volatile than the S&P 500. Comparatively, Xencor has a beta of 0.82, suggesting that its stock price is 18% less volatile than the S&P 500.
In the previous week, Xencor had 4 more articles in the media than Milestone Pharmaceuticals. MarketBeat recorded 9 mentions for Xencor and 5 mentions for Milestone Pharmaceuticals. Xencor's average media sentiment score of 0.94 beat Milestone Pharmaceuticals' score of 0.76 indicating that Xencor is being referred to more favorably in the news media.
Milestone Pharmaceuticals has a net margin of 0.00% compared to Xencor's net margin of -121.52%. Xencor's return on equity of -25.75% beat Milestone Pharmaceuticals' return on equity.
86.2% of Milestone Pharmaceuticals shares are owned by institutional investors. 19.5% of Milestone Pharmaceuticals shares are owned by insiders. Comparatively, 4.8% of Xencor shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.
Milestone Pharmaceuticals has higher earnings, but lower revenue than Xencor. Xencor is trading at a lower price-to-earnings ratio than Milestone Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.
Summary
Xencor beats Milestone Pharmaceuticals on 9 of the 16 factors compared between the two stocks.
Get Milestone Pharmaceuticals News Delivered to You Automatically
Sign up to receive the latest news and ratings for MIST and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding MIST and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Milestone Pharmaceuticals Competitors List
Related Companies and Tools
This page (NASDAQ:MIST) was last updated on 9/12/2025 by MarketBeat.com Staff
Free MIST Stock Alerts